1 Actuarial 1 and 3 year survival was 88% and 50% respecti
2 The
actuarial 1, 2, 3, and 4 years patient and graft surviva
3 The
actuarial 1-, 2-, and 3-year survival rates posttranspla
4 Actuarial 1-, 3-, and 5-year overall survival rates were
5 years (range, 1 to 12.9 years), with overall
actuarial 1-, 3-, and 5-year survival rates of 70%, 36%,
6 Actuarial 1-, 3-, and 5-year survivals were 85%, 60%, an
7 P=NS), early rejection (21 vs. 18%, P=NS) or
actuarial 1-year graft survival (96 vs. 90%, P=NS).
8 Actuarial 1-year graft survival was 91.7% with sirolimus
9 Actuarial 1-year overall survival (OS) and event-free su
10 The
actuarial 1-year pancreas graft survival was 87% for the
11 Actuarial 1-year patient and graft survival were 98.6% a
12 Actuarial 1-year patient survival was 91.7% with sirolim
13 The
actuarial 1-year patient survival was 93% for the PAK gr
14 nths (interquartile range, 3.1-37.1 months),
actuarial 1-year survival of 47.6%, and 2-year survival
15 se, and 8 (8%) underwent biopsy only with an
actuarial 1-year survival of 88%, 51%, and 47%, respecti
16 ents with a median follow-up of 11 years had
actuarial 10- and 15-year overall IBTR rates of 22% and
17 Actuarial 10-year disease-free survival was significantl
18 gins of <1 mm, 1 to 9 mm, and >or=10 mm, the
actuarial 10-year IBTR rates were 28%, 21%, and 19%, res
19 The
actuarial 10-year survival rates for the 136 SPKs were 9
20 Death-censored
actuarial 15-year graft survival rate was 56%.
21 Actuarial 15-year graft survival was 71% for nonrecurren
22 Estimated 5-year, 10-year, and
actuarial 15-year overall patients survival rates were 7
23 For living donor recipients, the
actuarial 15-year PS rates were similar between groups.
24 Actuarial 15-year survival was 60.6% (95% CI, 56.3%-64.9
25 xperienced BPAR (including borderline), with
actuarial 19% (14/75) vs. 18% (13/75) in groups A and B,
26 Actuarial 2-, 5- and 10-years overall- and disease-speci
27 Actuarial 2-year patient, graft, and rejection-free graf
28 The
actuarial 2-year rates of locoregional control and disea
29 Actuarial 2-year survival for Asians versus whites with
30 tal bone volume of more than 37.3% showed an
actuarial 2-year survival of 18%, compared with 82% for
31 followup of 34 months in the survivors, the
actuarial 2-year survival was 47%, the median survival w
32 The
actuarial 20-year patient survival rate was 38%; graft s
33 Actuarial 20-year survival was 52% (patient) and 42% (gr
34 The
actuarial 20-year survival was estimated at 45%.
35 with salvage radiation therapy, the overall
actuarial 3- and 5-year PSA relapse-free probabilities w
36 The
actuarial 3-year cancer-specific survival rate was 57% (
37 The
actuarial 3-year event-free and overall survival rates w
38 With a median follow-up of 37 months, the
actuarial 3-year relapse-free survival rate is 24% for t
39 The
actuarial 3-year relapse-free survival rate was 30% (95%
40 The estimated
actuarial 3-year survival of patients who survived at le
41 Actuarial 3-year survival rate was 30% after FAI and 35%
42 The
actuarial 3-year survival was 17%.
43 The
actuarial 4-month risk of death was 8.9%, 1.9%, and 1.2%
44 The
actuarial 4-year progression-free and overall survivals
45 The
actuarial 4-year survival rate for the entire group was
46 Actuarial 5- and 10-year survival was 52% and 43% (HTV o
47 The
actuarial 5- and 10-year survivals for patients who unde
48 Actuarial 5-year disease-free survival was 75% and five
49 odal disease at presentation had a decreased
actuarial 5-year disease-specific (0% v 45%, P =.004), d
50 Actuarial 5-year freedom from 2ndINT was 80%.
51 The
actuarial 5-year local and regional nodal control rates
52 This treatment resulted in an
actuarial 5-year local control and overall survival of 1
53 The
actuarial 5-year overall survival was 58% (95% confidenc
54 The
actuarial 5-year overall, disease-specific, disease-free
55 Actuarial 5-year patient survival was 94% in M and 95% i
56 After a median follow-up of 5.1 years, the
actuarial 5-year progression-free survival for all patie
57 The
actuarial 5-year survival for patients undergoing sphinc
58 Actuarial 5-year survival was 42% after resection for IP
59 adversely affect aneurysm-related or overall
actuarial 5-year survival.
60 te rejection in A2/A2B to B transplants, the
actuarial 7-year death censored graft survival was 72% f
61 The
actuarial 7-year disease-free survival rates were 81% an
62 The
actuarial 7-year overall survival rates were 85% for pat
63 on were compared with a previously described
actuarial algorithm.
64 Standard techniques for
actuarial analyses of potential prognostic variables (Ka
65 In
actuarial analysis among the initially medically managed
66 By
actuarial analysis in newly diagnosed CLL (n = 306), BIR
67 Actuarial analysis showed an incremental risk of lead fa
68 Actuarial analysis was used to project outcomes of patie
69 At the final
actuarial analysis when follow-up data were updated (Nov
70 On
actuarial analysis, freedom from appropriate shock at 1
71 By
actuarial analysis, the 12-month TLR and MACE rates were
72 By
actuarial analysis, the TAXUS stent compared with the ba
73 ed with the development of PN by exploratory
actuarial analysis.
74 genotypes was determined using Kaplan-Meier
actuarial analysis.
75 On an
actuarial basis, the rate of neoplastic progression was
76 sk category, AA and W men had similar 5-year
actuarial bNED rates in favorable (78% v 79%, P: = .91),
77 al clinical results are needed to complement
actuarial calculations of important end points from mult
78 The 10- and 15-year
actuarial cause-specific survival rates were 98.1% and 9
79 The
actuarial chance of not needing chemotherapy (non-lympho
80 Based on
actuarial characteristics of the 2002 U.S. population, p
81 The
actuarial complication-free survival rate was 71%.
82 The 5-year
actuarial cumulative rate of BKVN was 5.6%.
83 The
actuarial current progression-free survival (PFS) rate a
84 The dissimilarity of
actuarial curves between these two groups is consistent
85 Two-year
actuarial data showed a 75% local tumor control rate and
86 ced relative to historical controls based on
actuarial data.
87 Five-year
actuarial disease-free and overall survival rates were 8
88 e-year PFS was 22% (95% CI, 12%-32%); 5-year
actuarial distant metastasis and locoregional recurrence
89 vival (OS), progression-free survival (PFS),
actuarial distant metastasis, and locoregional recurrenc
90 At 24 months, the
actuarial estimate of stable treatment-free remission wa
91 Actuarial estimates for OS were calculated using Kaplan-
92 red the FLT3/ITD had worse clinical outcome;
actuarial event-free survival (EFS) at 4 years from stud
93 At 6 months, the
actuarial event-free survival (no acute rejection, allog
94 Actuarial event-free survival at 5 years was 70% versus
95 s, overall actuarial survival, response, and
actuarial event-free survival rates were 62%, 48%, and 2
96 1% with the majority being complete, and the
actuarial event-free survival was 58% in 44 treatment-na
97 However,
actuarial freedom from "heart death" (death or transplan
98 In early survivors,
actuarial freedom from death or transplantation was 93.7
99 patients implanted before 2000, the 4-month
actuarial freedom from driveline infections, bloodstream
100 Actuarial freedom from parenteral support among survivor
101 eratively (range, 3.6 to 30.6 months) for an
actuarial freedom from reoperation of 90% at 7 years.
102 served in the CMT group; in the RT group the
actuarial frequency of a second cancer was 16% at 20 yea
103 Actuarial graft and patient survival was similar in the
104 gnificant difference between groups in 15-yr
actuarial graft survival (GS) and death-censored (DC) GS
105 Actuarial graft survival at 1 and 4 years postconversion
106 The
actuarial graft survival at 6.3 years in the CAD DBMC gr
107 e did not observe significant differences in
actuarial graft survival at 8 yr post-transplant between
108 The 1, 3, and 5 year
actuarial graft survival in both living donor kidney aft
109 There is no difference in
actuarial graft survival in the two groups at 10 years (
110 The
actuarial graft survival in this group of 14 patients wa
111 n follow-up of 31 months, the death-censored
actuarial graft survival of dDSA recipients was worse th
112 ransplantation); corresponding 1- and 3-year
actuarial graft survival was 88% and 61%.
113 Subgroup
actuarial graft survival was determined.
114 no significant difference between groups in
actuarial graft survival.
115 The 8-year
actuarial graft survivals for the single- and dual-kidne
116 eriovenous malformations, but with increased
actuarial hemorrhage rates from the first to the fifth y
117 of these factors was associated with 5-year
actuarial IBTR-free and LRR-free survival rates of 87% t
118 Actuarial in-field local control rates at one and two ye
119 ths, 20 patients developed t-MDS/AML, for an
actuarial incidence of 6.8% at 10 years.
120 low-risk patients who were not screened, the
actuarial incidence of an IHD event after listing (befor
121 The 2-year
actuarial incidence of grade 3 to 5 radiation necrosis w
122 ter sparing procedure was 10% and the 5-year
actuarial incidence was 13%.
123 Kaplan-Meier estimates of the
actuarial incidence, which are based on censoring of pat
124 Observed survival was calculated by
actuarial life table methods for three new node-positive
125 Actuarial local control at one and two years after SBRT
126 The 5-year
actuarial local control rate was 94% (95% CI, 86% to 100
127 Actuarial local control rates of the 277 patients treate
128 for all patients), the overall 3- and 5-year
actuarial local recurrence rates were 11% and 13%, respe
129 disease treated at M.D. Anderson, the 5-year
actuarial local recurrence-free, distant recurrence-free
130 The 3-year
actuarial locoregional control was 82% and the 3-year ac
131 zed survival of both blacks and whites using
actuarial measures; presented outcomes within stage, adj
132 er a median follow-up time of 53 months, the
actuarial median survival time of all eligible patients
133 The 5-year
actuarial metastasis-free survival estimates (SE) were 9
134 k group, PSA outcome was estimated using the
actuarial method of Kaplan and Meier.
135 Overlooked is the question of whether such
actuarial methods are in fact mathematically justified,
136 st-feeding at 12 months was determined using
actuarial methods.
137 The
actuarial mortality rate was substantially lower among p
138 undergo transplantation or pump replacement,
actuarial mortality was 48.2% (95% CI, 31.6 to 65.2) in
139 Overall
actuarial one-year survival was 90%, and five-year survi
140 women with a first or only BC (BC-1 group),
actuarial OS and CSS were compared, accounting for age,
141 onths, median actuarial PFS is 17 months and
actuarial OS is 92 months.
142 and median OS was 47.4 months; 5 and 10-year
actuarial OS probabilities were 43% and 34%, respectivel
143 Our data suggests that 15-year
actuarial outcome (GS and DC GS) is worse for those deve
144 We analyzed the 15-year
actuarial overall patient survival (PS), graft survival
145 w-up of 36 months (range, 18-60 months), the
actuarial overall survival (OS) rates at 3 years were 34
146 The
actuarial overall survival and event-free survivals at 2
147 The
actuarial overall survival at 14 months was 53%, with a
148 Actuarial overall survival for the 1-, 2- and 3-year per
149 uing smokers (18 v 13.6 months), with 5-year
actuarial overall survival of 8.9% versus 4%, respective
150 Actuarial overall survival was calculated with Kaplan-Me
151 Actuarial overall survivals at 1-, 3-, and 5-year for th
152 Actuarial pancreas graft survival for SPK recipients at
153 In this series, 1-year
actuarial patient and allograft survival rates are 100%
154 Four-year
actuarial patient and graft survival for the DBMC-infuse
155 Actuarial patient and graft survival rates at 10 years w
156 Overall 5-year
actuarial patient and graft survival rates were 100% ver
157 Three-year
actuarial patient and graft survival rates were 95% and
158 One-year
actuarial patient and graft survival was 97% and 92%, re
159 Eight-year
actuarial patient and graft survivals in older individua
160 The overall 20-year
actuarial patient and graft survivals were 35.8% and 32.
161 The overall 20-year
actuarial patient and graft survivals were 35.8% and 32.
162 Overall 1- and 3-year
actuarial patient and liver allograft survival was 88% a
163 Three-year
actuarial patient and primary graft survival were 88% an
164 nance immunosuppression had excellent 4-year
actuarial patient survival (92%), graft survival (90%),
165 Actuarial patient survival at 1 and 3 years for group 1
166 Similarly,
actuarial patient survival at 10 years is 86% in both gr
167 The
actuarial patient survival rate at 3 years was 88%, and
168 Two-year
actuarial patient survival was 95% and 97%, and graft su
169 The 8-year
actuarial patient survivals for the single- and dual-kid
170 The 39-month Kaplan-Meier
actuarial patient survivals were 75.1% for CLTx and 88.6
171 The 1-year
actuarial patient, kidney, and pancreas survival rates i
172 Actuarial patient/graft survival at 48 months was 96%/91
173 One-year
actuarial patient/graft survival was 100%/100% in SPK, P
174 Three-year
actuarial patient/pancreas graft survival rates for SPK,
175 n potential follow-up of 28.3 months, median
actuarial PFS is 17 months and actuarial OS is 92 months
176 Actuarial-
predicted life expectancy, based on age and se
177 The primary end point was 2-year
actuarial primary tumor control; secondary end points we
178 The
actuarial probability of being alive and in remission at
179 a median follow-up period of 26 months, the
actuarial probability of current-event-free-survival at
180 The
actuarial probability of liver decompensation was lower
181 The
actuarial probability of PVT was lower in the enoxaparin
182 (69.6%) and 7 in group B (29%) survived; the
actuarial probability of survival at day 60 was 66% vers
183 The
actuarial probability of survival was higher in the enox
184 The
actuarial progression-free survival of 62% at 4 years is
185 Median
actuarial progression-free survival was 34 months.
186 an follow-up of 42 months, the 3- and 4-year
actuarial progression-free survivals were 71% and 62%, r
187 s no difference between groups in subsequent
actuarial PS, GS, and DCGS.
188 The 4-year
actuarial PSA relapse-free survival, distant metastasis-
189 9-43]), 44 (34%) had local regrowths (3-year
actuarial rate 38% [95% CI 30-48]); 36 (88%) of 41 patie
190 The 4-year
actuarial rate of DID was 13.5%.
191 locoregional control was 82% and the 3-year
actuarial rate of distant metastases was 19%.
192 lysis, factors significantly associated with
actuarial rate of first CVA included hypertension (P = .
193 tionships between potential risk factors and
actuarial rate of first stroke were analyzed.
194 The
actuarial rate of overall survival at 12 years was 76.3%
195 The
actuarial rate of R01 award attainment at 5 years was 22
196 By week 50, the
actuarial rate of treatment failure was 30.6% in the com
197 Actuarial rates of acute GVHD were 46% +/- 13% for grade
198 Crude and 2-year
actuarial rates of BM were 19% and 30%, respectively.
199 The 2-year
actuarial rates of elective nodal control and primary tu
200 The 5-year
actuarial rates of freedom from treatment failure (FFTF)
201 Five-year
actuarial rates of IBTR-free and LRR-free survival were
202 Actuarial rates of LR were calculated by using the Kapla
203 The 5- and 10-year
actuarial rates of LRR were both 27%.
204 ce rate was 10.3% (23 of 223), with a 5-year
actuarial recurrence-free rate of 0.84 +/- 0.03.
205 was 2.3% (two of 86), resulting in a 5-year
actuarial recurrence-free rate of 0.96 +/- 0.03.
206 e Kaplan-Meier method was used to assess the
actuarial recurrence-free survival on patients with graf
207 ined rejection-free during follow-up with an
actuarial rejection-free probability of 75% within 3 mon
208 11 patients (
actuarial relapse at 5 years 5.6%, 95% CI 2.3-8.9) given
209 Actuarial renal allograft survival rates were 53% at 1 a
210 The
actuarial risk for this complication has been estimated
211 eatment-related parameters, crude and 2-year
actuarial risk of BM were 27% and 39%, respectively, in
212 Actuarial risk of death from stage I breast cancer at 7
213 Twenty-five years after HD diagnosis, the
actuarial risk of developing a solid tumor was 21.9%.
214 ed patients, progression-free survival (PFS;
actuarial +/-
SE) was 61% +/- 7% and survival was 58% +/
215 The
actuarial senescence (i.e., the rate of increase in adul
216 While previous research has demonstrated
actuarial senescence in this population, as does this st
217 Recent examples of
actuarial senescence in wild insect populations have cha
218 Among families of mammals,
actuarial senescence was related to extrinsic mortality
219 terminal investment can produce a signal of
actuarial senescence.
220 n mechanisms that postpone physiological and
actuarial senescence.
221 can evolve in the absence of reproductive or
actuarial senescence; this implies that maternal effect
222 Actuarial survival after completed stage 2 was 71% at 5
223 Estimated
actuarial survival after continuous-flow left ventricula
224 Five-year
actuarial survival after heart transplantation was 58%.
225 Actuarial survival among these surgically salvaged patie
226 Actuarial survival analysis using Kaplan-Meier curves, C
227 ogistic regression analysis and Kaplan-Meier
actuarial survival analysis.
228 l for the entire group was 9 months, and the
actuarial survival at 1 and 2 years was 42% and 23%, res
229 is 366 days (95% CI 185, not estimable) and
actuarial survival at 1 year is 52%.
230 Actuarial survival at 1 year was 55%, progression-free s
231 Actuarial survival at 1, 5, and 10 years for Group I was
232 Actuarial survival at 10 years from diagnosis of second
233 Actuarial survival at 10 years was 97% (SD 2) in the aut
234 Actuarial survival at 3 years was 70%, and 3-year event-
235 atients (6%) died from lymphoma; the overall
actuarial survival at 3 years was 95%.
236 Actuarial survival at 5 and 10 years was 72.4% (95% conf
237 There was no perioperative mortality and
actuarial survival at 5 years was 94.6%.
238 Actuarial survival at 5, 10, 15, and 20 years was 93% (9
239 Overall
actuarial survival at 7 years was 55%.
240 Actuarial survival at two years was 98.2% among patients
241 Actuarial survival curves were plotted according to the
242 The overall 20-year
actuarial survival for pediatric liver transplantation i
243 Two-year
actuarial survival for the induction group was 93.2% com
244 re no significant differences in the 10-year
actuarial survival from transplant between groups.
245 For the validation cohort 2, the
actuarial survival from transplant for the M+ group was
246 had a 90-day mortality of 39.7% and a 1-year
actuarial survival of 54.5% compared with 6.9% and 88.6%
247 Actuarial survival of BK-positive grafts was worse than
248 Actuarial survival on support was 72% (95% confidence in
249 The 1-, 3-, and 5-year
actuarial survival rate differed between the study and c
250 The
actuarial survival rate for the total population was 75%
251 2) with 2 late deaths (1.6%), for an overall
actuarial survival rate of 96.3% at 7 years.
252 he median survival was 17 months, and 2-year
actuarial survival rate was 40% (95% confidence interval
253 an, 40 years; range, 20-44 years) the 5-year
actuarial survival rate was 87.5% (95% CI, 86.5%-88.4%)
254 The
actuarial survival rate was 90% at 5 years, freedom from
255 The 5-year
actuarial survival rate was 96.7% (95% CI, 94.1%-99.3%)
256 One-year and 5-year
actuarial survival rates are high, approximately 75% and
257 ts with continuous-flow devices had superior
actuarial survival rates at 2 years (58% vs. 24%, P=0.00
258 Actuarial survival rates at 6 years were as follows: JMM
259 Differences were found in 1-, 3-, and 5-year
actuarial survival rates between the I-CC subgroup and t
260 The
actuarial survival rates for 1, 3, and 5 years for group
261 Five-year
actuarial survival rates for all exposure groups, age-ad
262 The 5-year
actuarial survival rates for more pediatric-specific can
263 tire group was 13 months, with 1- and 2-year
actuarial survival rates of 61% and 29%, respectively.
264 The 1-, 2-, and 3-year
actuarial survival rates of all 150 patients were 54%, 1
265 Actuarial survival rates related to prognostic determina
266 applicator (5 cm or 6 cm), the 2- and 3-year
actuarial survival rates were 27% and 17%, respectively.
267 entire group was 14.4 months; 1- and 2-year
actuarial survival rates were 57% and 25%, respectively.
268 One and five-year
actuarial survival rates were 85%/64% for adult and 90%/
269 Actuarial survival rates were 91% at 1 year, 88% at 3 ye
270 f 13.3 years, the 10-, 20-, 30-, and 40-year
actuarial survival rates were 93%, 79%, 59%, and 26%, re
271 Actuarial survival rates were 93.3%, 86.4%, and 73.5% at
272 llow-up of 29 months, the 1-, 3-, and 5-year
actuarial survival rates were 97%, 74%, and 58%; median
273 Actuarial survival rates were much lower for blacks than
274 Three year
actuarial survival revealed no difference between groups
275 Kaplan-Meier
actuarial survival was 24 months, with actual 3 and 5 ye
276 who underwent curative resection, the 5-year
actuarial survival was 41%, with a median survival of 48
277 Actuarial survival was 60+/-12% versus 92+/-5% (P<0.005)
278 , median actuarial TTP was 43 wk, and median
actuarial survival was 70 wk.
279 The
actuarial survival was 70% at 5 years and the aneurysm-r
280 tor of increased all-cause mortality: 1 year
actuarial survival was 79 +/- 5% in the nonfrail group c
281 The 5-year disease-specific
actuarial survival was 79% (78% for patients treated fro
282 At 10 years, the overall
actuarial survival was 88%, the response rate was 71% wi
283 The overall 4-year estimated
actuarial survival was 89% (95% CI 82-94).
284 Actuarial survival was 97% and 90% (P=0.30), and surviva
285 Actuarial survival was calculated using the Kaplan-Meier
286 When
actuarial survival was estimated, cohorts with < or = 25
287 Actuarial survival was greater in the MMF group compared
288 tcome between matched groups, but the 5-year
actuarial survival was higher in patients with thromboly
289 Actuarial survival was measured from the initiation of r
290 Actuarial survival with freedom from parenteral support
291 The 4-year estimated
actuarial survival with native liver was 51% (42-59%).
292 fully rescued with retransplantation (30-day
actuarial survival, 97.1% SLD vs. 94.1% LRD, P=0.745).
293 The 5-year
actuarial survival, disease-free survival, and bNED rate
294 clophosphamide therapy; at 10 years, overall
actuarial survival, response, and actuarial event-free s
295 perioperative mortality (chi(2)) and 5-year
actuarial survival.
296 fe expectancy of the general population from
actuarial tables: 80 to 84 years (7 years) and > or =85
297 e 27 patients who could be evaluated, median
actuarial TTP was 43 wk, and median actuarial survival w
298 nce rate was 5.4% (13 of 242), with a 5-year
actuarial tumor recurrence-free rate of 0.88 +/- 0.03.
299 estimate the cumulative incidence over time (
actuarial v cumulative calculations), up to 10% of NHL p
300 The
actuarial yearly failure rate was 2.3% for non-Fidelis a